Acute Myeloid Leukemia: 2025 Update on Diagnosis, Risk‑Stratification, and Management
This review summarizes the rapid evolution of diagnostic, prognostic, and therapeutic strategies for AML, highlighting the impact of 12 newly approved agents and precision‑based risk stratification on patient outcomes.
Acute myeloid leukemia (AML) is a bone marrow stem cell cancer that is often fatal despite available treatments. Diagnosis, risk assessment, monitoring, and therapeutic management of AML have changed dramatically in the last decade due to increased pathophysiologic understanding, improved assessment technology, and the addition of at least 12 approved therapies. The article reviews novel diagnostic classifications, molecular biomarkers, measurable residual disease monitoring, and risk‑adapted therapeutic regimens.
AML is a rapidly fatal disease with poor survival outcomes, yet recent advances in molecular diagnostics, risk stratification, and targeted therapies are improving prognosis and guiding personalized treatment strategies for patients worldwide.
Evidence level: Megerősített klinikai bizonyíték. Több vagy erősebb humán vizsgálat támogatja.
Related signals
- Can natural killer cells cure leukemia?
- MAPK-ERK is a central pathway in T-cell acute lymphoblastic leukemia that drives steroid resistance
- Advancing Leukemia Diagnosis and Treatment: WHO-Supported Laboratory Innovations in Africa- A Narrative Review
- Immunotherapy for leukemia may change the bone marrow environment, cancer researchers find
- Next-generation CAR‑T therapy for acute myeloid leukemia: bridging innovation with clinical translation